1. Home
  2. CRVO vs SCLX Comparison

CRVO vs SCLX Comparison

Compare CRVO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CervoMed Inc.

CRVO

CervoMed Inc.

HOLD

Current Price

$2.27

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$2.77

Market Cap

27.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVO
SCLX
Founded
2001
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9M
27.9M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
CRVO
SCLX
Price
$2.27
$2.77
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $15.00
N/A
AVG Volume (30 Days)
★ 275.4K
38.9K
Earning Date
11-09-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
$4,006,510.00
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
$525.01
$186.31
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.13
$2.77
52 Week High
$10.00
$27.00

Technical Indicators

Market Signals
Indicator
CRVO
SCLX
Relative Strength Index (RSI) 37.11 20.68
Support Level $2.13 N/A
Resistance Level $3.32 $7.77
Average True Range (ATR) 0.23 0.34
MACD -0.10 -0.07
Stochastic Oscillator 12.21 3.78

Price Performance

Historical Comparison
CRVO
SCLX

About CRVO CervoMed Inc.

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: